Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species

Journal of Orthopaedic Research

Volumn 30, Issue 11, 2012, Pages 1843-1852

  Jia, Peng ^a   Xu, You Jia ^a   Zhang, Zeng Li ^b   Li, Kai ^c   Li, Bingyan ^b   Zhang, Wen ^c   Yang, Huilin ^d  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

iron; osteoclast; reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; FERRIC AMMONIUM CITRATE; FERRIC ION; GLUTATHIONE; GLUTATHIONE DISULFIDE; OSTEOCLAST DIFFERENTIATION FACTOR; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLCYSTEINE; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; FERRIC COMPOUNDS; GLUTATHIONE; IRON; MALE; MICE; MICE, INBRED ICR; OSTEOCLASTS; OXIDATIVE STRESS; QUATERNARY AMMONIUM COMPOUNDS; RANK LIGAND; REACTIVE OXYGEN SPECIES;

EID: 84867233063     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22133     Document Type: Article

References (43)

1. Organiazation WH., 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843: 1-129.
2. Christenson RH., 1997. Biochemical markers of bone metabolism: an overview. Clin Biochem 30: 573-593.
3. Mackenzie EL, Iwasaki K, Tsuji Y., 2008. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 10: 997-1030.
4. Weinberg ED., 2006. Iron loading: a risk factor for osteoporosis. Biometals 19: 633-635.
5. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. 2005. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16: 1809-1814.
6. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, et al. 2003. Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 18: 1682-1688.
7. Sadat-Ali M, Sultan O, Al-Turki H, et al. 2011. Does high serum iron level induce low bone mass in sickle cell anemia ? Biometals 24: 19-22.
8. Jian J, Pelle E, Huang X., 2009. Iron and menopause: does increased iron affect the health of postmenopausal women ? Antioxid Redox Signal 11: 2939-2943.
9. Yamasaki K, Hagiwara H., 2009. Excess iron inhibits osteoblast metabolism. Toxicol Lett 191: 211-215.
10. Zarjou A, Jeney V, Arosio P, et al. 2010. Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res 25: 164-172.
11. Yang Q, Jian J, Abramson SB, et al. 2011. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 26: 1188-1196.
12. Tsay J, Yang Z, Ross FP, et al. 2010. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 116: 2582-2589.
13. Ishii K, Fumoto T, Iwai K, et al. 2009. Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15: 259-266.
14. Abdollahi M, Larijani B, Rahimi R, et al. 2005. Role of oxidative stress in osteoporosis. Therapy 2: 787-796.
15. Fatokun AA, Stone TW, Smith RA., 2008. Responses of differentiated MC3T3-E1 osteoblast-like cells to reactive oxygen species. Eur J Pharmacol 587: 35-41.
16. Kim H, Kim IY, Lee SY, et al. 2006. Bimodal actions of reactive oxygen species in the differentiation and bone-resorbing functions of osteoclasts. FEBS Lett 580: 5661-5665.
17. Lee NK, Choi YG, Baik JY, et al. 2005. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852-859.
18. Ha H, Bok Kwak H, Woong Lee S, et al. 2004. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301: 119-127.
19. Jomova K, Valko M., 2011. Advances in metal-induced oxidative stress and human disease. Toxicology 283: 65-87.
20. Huh Y, Kim J, Kim H, et al. 2005. Regulation of osteoclast differentiation by the redox-dependent modulation of nuclear import of transcription factors. Cell Death Differ 13: 1138-1146.
21. Sul OJ, Kim JC, Kyung TW, et al. 2010. Gold nanoparticles inhibited the receptor activator of nuclear factor-KB ligand (RANKL)-induced osteoclast formation by acting as an antioxidant. Biosci Biotechnol Biochem 74: 2209-2213.
22. Takayanagi H., 2007. The role of NFAT in osteoclast formation. Ann NY Acad Sci 1116: 227-237.
23. Takayanagi H, Kim S, Koga T, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
24. Chasteen ND, Harrison PM., 1999. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol 126: 182-194.
25. Baek KH, Oh KW, Lee WY, et al. 2010. Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. Calcif Tissue Int 87: 226-235.
26. Ozgocmen S, Kaya H, Fadillioglu E, et al. 2007. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem 295: 45-52.
27. Huang J, Jones D, Luo B, et al. 2011. Iron overload and diabetes risk: a shift from glucose to fatty acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes 60: 80-87.
28. Salvador GA., 2010. Iron in neuronal function and dysfunction. BioFactors 36: 103-110.
29. Toyokuni S., 2009. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100: 9-16.
30. Howes PS, Zacharski LR, Sullivan J, et al. 2000. Role of stored iron in atherosclerosis 1. J Vasc Nurs 18: 109-116.
31. Weinberg E., 2008. Role of iron in osteoporosis. Pediatr Endocrinol Rev 6: 81-85.
32. Liu G, Men P, Kenner GH, et al. 2008. Therapeutic effects of an oral chelator targeting skeletal tissue damage in experimental postmenopausal osteoporosis in rats. Hemoglobin 32: 181-190.
33. Liu G, Men P, Kenner GH, et al. 2006. Age-associated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals 19: 245-251.
34. Kudo H, Suzuki S, Watanabe A, et al. 2008. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology 246: 143-147.
35. Matsushima S, Hoshimoto M, Torii M, et al. 2001. Iron lactate-induced osteopenia in male Sprague-Dawley rats. Toxicol Pathol 29: 623-629.
36. Schafer FQ, Buettner GR., 2001. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Bio Med 30: 1191-1212.
37. Cadenas E, Davies KJA., 2000. Mitochondrial free radical generation, oxidative stress, and aging1. Free Radical Med 29: 222-230.
38. Hordijk PL., 2006. Regulation of NADPH Oxidases. Circ Res 98: 453-462.
39. Green DR, Reed JC., 1998. Mitochondria and apoptosis. Science 281: 1309-1312.
40. Xu Y, Morse LR, da Silva RAB, et al. 2011. PAMM: a redox regulatory protein that modulates osteoclast differentiation. Antioxid Redox Signal 13: 27-37.
41. Boyle WJ, Simonet WS, Lacey DL., 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
42. Henriksen K, Tanko L, Qvist P, et al. 2007. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18: 681-685.
43. Bai X, Lu D, Liu A, et al. 2005. Reactive oxygen species stimulates receptor activator of NF-KB ligand expression in osteoblast. J Biol Chem 280: 17496-17506.